HighTower Advisors’s Cognition Therapeutics CGTX Stock Holding History

HighTower Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.5K	Buy	26,500 +2,500	+10%	+$2.96K	﹤0.01%	3753
2026 Q1	$18.2K	Hold	24,000	–	–	﹤0.01%	3764
2025 Q4	$32.4K	Sell	24,000 -500	-2%	-$812	﹤0.01%	3594
2025 Q3	$33.1K	Buy	24,500 +7,500	+44%	+$10.2K	﹤0.01%	3642
2025 Q2	$5.27K	Sell	17,000 -7,462	-31%	-$2.52K	﹤0.01%	3673
2025 Q1	$10.3K	Buy	24,462 +5,000	+26%	+$2.94K	﹤0.01%	3556
2024 Q4	$13.6K	Sell	19,462 -3,500	-15%	-$1.73K	﹤0.01%	3569
2024 Q3	$11K	Hold	22,962	–	–	﹤0.01%	3544
2024 Q2	$38K	Hold	22,962	–	–	﹤0.01%	3335
2024 Q1	$41K	Sell	22,962 -10,000	-30%	-$20.6K	﹤0.01%	3281
2023 Q4	$61K	Hold	32,962	–	–	﹤0.01%	3270
2023 Q3	$47K	Buy	32,962 +6,401	+24%	+$10K	﹤0.01%	3238
2023 Q2	$48K	Sell	26,561 -2,000	-7%	-$4.23K	﹤0.01%	3167
2023 Q1	$58K	Buy	+28,561	New	+$54.4K	﹤0.01%	3029

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

HighTower Advisors's CGTX Position: Q2 2026 in Review

HighTower Advisors increased its Cognition Therapeutics (CGTX) stake by 10% in Q2 2026, buying an estimated $2.96K and bringing the position to 26,500 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3753.

HighTower Advisors first reported a position in CGTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $61K in Q4 2023. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

HighTower Advisors held 26,500 shares of Cognition Therapeutics worth $30.5K as of Q2 2026.
HighTower Advisors bought 2,500 Cognition Therapeutics shares in Q2 2026, an estimated $2.96K.
Cognition Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3753 holding.
HighTower Advisors first reported a position in Cognition Therapeutics in Q1 2023 and has held it in 14 quarters since.
HighTower Advisors's Cognition Therapeutics position peaked at $61K in Q4 2023.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.